731 related articles for article (PubMed ID: 28449664)
41. [Clinicopathologic features and differential diagnosis of multilocular cystic renal cell carcinoma].
Zhang W; Li Y; Lu Q; Zhuang J; Wang Q; Zhao H; Yu W; Kang E; Feng Z
Zhonghua Bing Li Xue Za Zhi; 2014 Nov; 43(11):723-7. PubMed ID: 25582248
[TBL] [Abstract][Full Text] [Related]
42. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract][Full Text] [Related]
43. Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation: Clinicopathologic Correlation and Molecular Findings.
Gama A; Xu H; Yang XJ; Choy B
Int J Surg Pathol; 2024 Feb; 32(1):11-16. PubMed ID: 37063043
[No Abstract] [Full Text] [Related]
44. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.
de Peralta-Venturina M; Moch H; Amin M; Tamboli P; Hailemariam S; Mihatsch M; Javidan J; Stricker H; Ro JY; Amin MB
Am J Surg Pathol; 2001 Mar; 25(3):275-84. PubMed ID: 11224597
[TBL] [Abstract][Full Text] [Related]
45. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
[TBL] [Abstract][Full Text] [Related]
46. Chromophobe renal cell carcinoma with sarcomatoid change. A case report.
Nagashima Y; Okudela K; Osawa A; Nakamura N; Kawasaki C; Moriyama M; Nakamura N; Nakatani Y; Kitamura H; Aoki I
Pathol Res Pract; 2000; 196(9):647-51; discussion 652. PubMed ID: 10997740
[TBL] [Abstract][Full Text] [Related]
47. Significant variation of immunohistochemical marker expression in paired primary and metastatic clear cell renal cell carcinomas.
Pan Z; Grizzle W; Hameed O
Am J Clin Pathol; 2013 Sep; 140(3):410-8. PubMed ID: 23955461
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
Zhao Z; Liao G; Li Y; Zhou S; Zou H; Fernando S
PLoS One; 2014; 9(11):e114096. PubMed ID: 25426861
[TBL] [Abstract][Full Text] [Related]
49. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
Büscheck F; Fraune C; Simon R; Kluth M; Hube-Magg C; Möller-Koop C; Shadanpour N; Bannenberg C; Eichelberg C; Höflmayer D; Clauditz T; Wittmer C; Wilczak W; Sauter G; Fisch M; Rink M; Eichenauer T
Urol Oncol; 2018 Dec; 36(12):531.e19-531.e25. PubMed ID: 30322727
[TBL] [Abstract][Full Text] [Related]
50. A novel prognostic model for patients with sarcomatoid renal cell carcinoma.
Zhang BY; Thompson RH; Lohse CM; Leibovich BC; Boorjian SA; Cheville JC; Costello BA
BJU Int; 2015 Mar; 115(3):405-11. PubMed ID: 24730416
[TBL] [Abstract][Full Text] [Related]
51. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
[TBL] [Abstract][Full Text] [Related]
52. Sarcomatoid conversion of clear cell renal cell carcinoma in relation to epithelial-to-mesenchymal transition.
Boström AK; Möller C; Nilsson E; Elfving P; Axelson H; Johansson ME
Hum Pathol; 2012 May; 43(5):708-19. PubMed ID: 21992819
[TBL] [Abstract][Full Text] [Related]
53. Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects.
Kuroda N; Toi M; Hiroi M; Enzan H
Histol Histopathol; 2003 Apr; 18(2):551-5. PubMed ID: 12647806
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma: An Analysis of 22 Cases.
Whaley RD; Cheng L
Am J Surg Pathol; 2022 Sep; 46(9):1171-1179. PubMed ID: 35687360
[TBL] [Abstract][Full Text] [Related]
56. Chromophobe renal cell carcinoma: an immunohistochemical study of 21 Japanese cases.
Taki A; Nakatani Y; Misugi K; Yao M; Nagashima Y
Mod Pathol; 1999 Mar; 12(3):310-7. PubMed ID: 10102617
[TBL] [Abstract][Full Text] [Related]
57. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
[TBL] [Abstract][Full Text] [Related]
58. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Zhang BY; Thompson RH; Lohse CM; Dronca RS; Cheville JC; Kwon ED; Leibovich BC
BJU Int; 2013 Jun; 111(7):1046-53. PubMed ID: 23551810
[TBL] [Abstract][Full Text] [Related]
59. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
60. Co-existence of epithelioid and fibroblastoid subsets in a sarcomatoid renal carcinoma cell line revealed by clonal studies.
Hsieh CH; Chen HC; Chang YH; Pang ST; Kuo ML; Chuang CK; Liao SK
Anticancer Res; 2013 Nov; 33(11):4875-89. PubMed ID: 24222125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
